Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

New Contract Signed with ScandiNova

22 Jul 2014 07:00

RNS Number : 9237M
Advanced Oncotherapy PLC
22 July 2014
 



22 July2014

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

 

Contract Signed with ScandiNova Systems AB

 

Advanced Oncotherapy (AIM: AVO), the developer of the next generation of particle therapy using protons to treat cancer, announces that it has entered into a collaboration with industry leader ScandiNova Systems AB ("ScandiNova"). ScandiNova will develop the high energy systems that will power the unit of the proprietary LIGHT system which will create the proton beam.

 

ScandiNova was founded in 2001 to commercialise technical expertise in pulsed power applications including Radiotherapy, Radar, industrial X-ray and scientific accelerator systems. The company is located in Uppsala, Sweden and has established a global network of collaborations with highly skilled and experienced partners covering industry, academia and research organisations such as CERN in Europe, Lawrence Livermore and Brookhaven National Laboratories in the US.

ScandiNova specialises in the development of solid state controlled power systems which require about one third of the space and are 30% more efficient than those used in standard, older technology - synchrotrons.

Mikael Lindholm, Founder, Senior VP Sales & Marketing ScandiNova, commented: "We have been working with ADAM since 2007 and from the very start have seen the potential in the LIGHT technology which should deliver a superior proton therapy technology. Our Solid State Pulse Power products are widely used and are now installed in 28 different countries in Europe, Asia, Australia, and North and South America. For us, it is a privilege to be working with an organisation which could become the number one supplier of the next generation of proton therapy. "

 

Sanjeev Pandya, CEO of Avdanced Oncotherapy, added: "In our due diligence prior to the acquisition of the LIGHT technology, it became clear that there were already many world class partners involved in the development of the LIGHT programme. ScandiNova is one such partner and I am really pleased to be able to make this announcement. Advanced Oncotherapy is going to continue this relationship and ScandiNova will become a key partner and supplier in helping us develop our complete LIGHT system."

 

For further information contact:

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya (CEO)

Tel: +44 20 3617 8739

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten

 

Beaufort Securities (Joint Broker)

 

Tel: +44 20 7382 8300

Saif Janjua / Jon Levinson

 

 

Walbrook PR (Financial PR & IR)

avo@walbrookpr.com

Anna Dunphy / Mike Wort

 

Tel: +44 20 7933 8780

 

About Advanced Oncotherapy Plc

 

Mission:

To facilitate the wider use of particle therapy with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider.

 

Key corporate messages:

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This LIGHT system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

AVO is a provider of proton radiotherapy that harnesses the best in modern technology. As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

 

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

For more information, please visit http://www.avoplc.com

 

About ScandiNova

 

ScandiNova Systems AB is a company based in Uppsala, Sweden. The company has an office in USA and representatives in 8 other countries. The company is growing continuously, since many customers in various applications are leaving the old traditional technology.

 

ScandiNova provides advanced high power Pulse Generators and fully integrated RF units, providing RF power up to 100MW and voltage pulses up to 500kV. The ScandiNova products are based on a unique patented Solid State parallel switching technology, which provides very high reliability and exceptional pulse quality and precision. Additionally, the power consumption is about 30% less than the traditional technology, which in high power applications is an important environmental requirement.

 

ScandiNova is supported by its main strong owners SEB Ventures (part of the biggest Swedish Bank SEB) and Industrifonden (the biggest government initiated fund).

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTVFLFLZDFFBBQ
Date   Source Headline
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters
1st Mar 20232:05 pmRNSSecond Price Monitoring Extn
1st Mar 20232:00 pmRNSPrice Monitoring Extension
27th Jan 20234:53 pmEQSHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
18th Jan 20232:00 pmRNSOperational update
17th Jan 20233:10 pmEQSHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
30th Dec 20221:00 pmRNSTotal Voting Rights
30th Dec 20229:24 amRNSDirector/PDMR Shareholding
29th Dec 20223:12 pmRNSDirector/PDMR Shareholding
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 202212:40 pmRNSSecond Price Monitoring Extn
23rd Dec 202212:35 pmRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSEquity Subscription and Issue of Warrants
1st Dec 20227:00 amRNSIssue of Equity
28th Nov 20227:00 amRNSStudy showcases the potential superiority of LIGHT
3rd Nov 20223:20 pmRNSInvestor / Analyst Event Update
31st Oct 20225:00 pmRNSTotal Voting Rights
27th Oct 20227:31 amRNSPresentation highlights superiority of LIGHT
21st Oct 20227:00 amRNSNotice of Investor / Analyst Event
18th Oct 20227:00 amRNSEquity Subscription and Issue of Warrants
30th Sep 20225:00 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSInterim Results
29th Sep 20227:15 amEQSHardman & Co Research on Advanced Oncotherapy: Major milestone achieved
27th Sep 202210:30 amRNSLIGHT accelerator fully operational
31st Aug 20225:00 pmRNSTotal Voting Rights
23rd Aug 20223:09 pmRNSUpdate re admission of Subscription Shares
19th Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
17th Aug 20225:30 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
29th Jul 20224:30 pmRNSResult of AGM
7th Jul 202212:30 pmRNSHolding(s) in Company
30th Jun 20225:00 pmRNSTotal Voting Rights
30th Jun 20229:00 amRNSFinal results for the year ended 31 December 2021
28th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
13th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
31st May 20225:00 pmRNSTotal Voting Rights
27th May 202212:17 pmRNSHolding(s) in Company
11th May 20227:00 amRNSLIGHT system potential in delivering FLASH
29th Apr 20225:00 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNSVideo showcases progress on LIGHT system process
26th Apr 20227:00 amRNSOperational update
22nd Apr 20227:00 amRNSUpdate re admission of Subscription Shares
19th Apr 20224:05 pmRNSUpdate re admission of Subscription Shares
12th Apr 20227:13 amRNSEquity Subscription and Issue of Warrants
31st Mar 20225:00 pmRNSTotal Voting Rights
25th Mar 20229:30 amRNS£2m Subscription, Add'l Loan and Issue of Warrants
14th Mar 20227:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
4th Mar 20229:00 amRNSDirector/PDMR Notification
3rd Mar 20226:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.